An add-on strategy to maximize workouts: electro stimulation works for cancer patients
/0 Comments/in Clinical Trial, Metastatic/by MaxUnlocking the Fortress: Good News for Immunotherapy Directed to Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 3 trial: 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxA Phase 1 trial to keep an eye on: Thorium-227 (BAY2315497) in metastatic Castration Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxBenfo-Oxythiamine Shows Promise as a Radiosensitizer in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPositive Phase 1 Data Supports Phase 2 of 177Lu rhPSMA-10.1 for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFDA Accepts New Drug Application for 3-Month Formulation of Leuprolide Mesylate for Advanced Prostate Cancer Treatment
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 2: Iodine-131 PSMA Radioligand with Enzalutamide Shows Promise in ARROW trial for metastatic castration-resistant prostate cancer (mCRPC)
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial theranostics
Latest Posts
- Newsletter 37/2025 September 14, 2025
- OST-504: A Novel Immunotherapy Targeting Prostate Cancer September 13, 2025
- Memantine Shows Promise Against Advanced Prostate Cancer September 11, 2025
- Pasritamig in Late-Line Prostate Cancer: From Early Findings to the KLK2-comPAS Trial September 11, 2025